Furin Targeted Drug Delivery for Treatment of Rhabdomyosarcoma in a Mouse Model

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. Improvement of treatment efficacy and decreased side effects through tumor-targeted drug delivery would be desirable. By panning with a phage-displayed cyclic random peptide library we selected a peptide with strong affinity for RMS in vitro and in vivo. The peptide minimal binding motif Arg-X-(Arg/Lys)(Arg/Lys) identified by alanine-scan, suggested the target receptor to be a proprotein convertase (PC). Expression profiling of all PCs in RMS biopsies and cell lines revealed consistent high expression levels for the membrane-bound furin and PC7. Direct binding of RMS-P3 peptide to furin was demonstrated by affinity chromatography and supported by activity and colocalization studies. Treatment of RMS in mice with doxorubicin coupled to the targeting peptide resulted in a two-fold increase in therapeutic efficacy compared to doxorubicin treatment alone. Our findings indicate surface-furin binding as novel mechanism for therapeutic cell penetration which needs to be further investigated. Furthermore, this work demonstrates that specific targeting of membrane-bound furin in tumors is possible for and suggests that RMS and other tumors might benefit from proprotein convertases targeted drug delivery.

[1]  E. Ruoslahti,et al.  Vascular zip codes in angiogenesis and metastasis. , 2004, Biochemical Society transactions.

[2]  N. Seidah,et al.  Evidence that furin is an authentic transforming growth factor-beta1-converting enzyme. , 2001, The American journal of pathology.

[3]  A. Strongin,et al.  Selective and potent furin inhibitors protect cells from anthrax without significant toxicity. , 2010, The international journal of biochemistry & cell biology.

[4]  Fabien Calvo,et al.  Opposing function of the proprotein convertases furin and PACE4 on breast cancer cells' malignant phenotypes: role of tissue inhibitors of metalloproteinase-1. , 2007, Cancer research.

[5]  C. Dubois,et al.  Furin gene (fur) regulation in differentiating human megakaryoblastic Dami cells: involvement of the proximal GATA recognition motif in the P1 promoter and impact on the maturation of furin substrates. , 2002, Blood.

[6]  R. Herrmann,et al.  Overview of monoclonal antibodies in cancer therapy: present and promise. , 2005, Critical reviews in oncology/hematology.

[7]  R. Leduc,et al.  Subtilase-like pro-protein convertases: from molecular specificity to therapeutic applications. , 2000, Journal of molecular endocrinology.

[8]  K. Alitalo,et al.  Proprotein convertases promote processing of VEGF‐D, a critical step for binding the angiogenic receptor VEGFR‐2 , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  C Di Bello,et al.  Identification of the Paired Basic Convertases Implicated in HIV gp160 Processing Based on in Vitro Assays and Expression in CD4+ Cell Lines* , 1996, The Journal of Biological Chemistry.

[10]  W. Arap,et al.  Combinatorial Targeting of the Macropinocytotic Pathway in Leukemia and Lymphoma Cells* , 2008, Journal of Biological Chemistry.

[11]  S. Takahashi,et al.  A Second Mutant Allele of Furin in the Processing-incompetent Cell Line, LoVo , 1995, The Journal of Biological Chemistry.

[12]  P. Lollini,et al.  Molecular and cellular biology of rhabdomyosarcoma. , 2009, Future oncology.

[13]  W. Meyer,et al.  Rhabdomyosarcoma: new windows of opportunity. , 2005, The oncologist.

[14]  G. Thomas,et al.  alpha1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Basak,et al.  A Novel Enediynyl Peptide Inhibitor of Furin That Blocks Processing of proPDGF-A, B and proVEGF-C , 2009, PloS one.

[16]  B. Schäfer,et al.  Molecular features of a human rhabdomyosarcoma cell line with spontaneous metastatic progression , 2000, British Journal of Cancer.

[17]  N. Katunuma,et al.  Processing protease for gp160 human immunodeficiency virus type I envelope glycoprotein precursor in human T4+ lymphocytes. Purification and characterization. , 1993, The Journal of biological chemistry.

[18]  Erkki Ruoslahti,et al.  Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. , 2008, Cancer research.

[19]  S. Futaki.  Oligoarginine vectors for intracellular delivery: design and cellular-uptake mechanisms. , 2006, Biopolymers.

[20]  E. Fleck,et al.  Proprotein convertases regulate insulin-like growth factor 1-induced membrane-type 1 matrix metalloproteinase in VSMCs via endoproteolytic activation of the insulin-like growth factor-1 receptor. , 2004, Biochemical and biophysical research communications.

[21]  Erkki Ruoslahti,et al.  Tissue-penetrating delivery of compounds and nanoparticles into tumors. , 2009, Cancer cell.

[22]  D. Bassi,et al.  Proprotein convertases: “Master switches” in the regulation of tumor growth and progression , 2005, Molecular carcinogenesis.

[23]  N. Seidah,et al.  The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. , 2003, The Journal of clinical investigation.

[24]  Kit S Lam,et al.  From combinatorial chemistry to cancer-targeting peptides. , 2007, Molecular pharmaceutics.

[25]  M. Weller,et al.  BCL‐2‐induced glioma cell invasiveness depends on furin‐like proteases , 2004, Journal of neurochemistry.

[26]  N. Seidah,et al.  Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells. , 2008, The Journal of clinical investigation.

[27]  B. Schäfer,et al.  Identification of a rhabdomyosarcoma targeting peptide by phage display with sequence similarities to the tumour lymphatic‐homing peptide LyP‐1 , 2009, International journal of cancer.

[28]  A. Klein-Szanto,et al.  Elevated furin expression in aggressive human head and neck tumors and tumor cell lines , 2001, Molecular carcinogenesis.

[29]  Annik Prat,et al.  The proprotein convertase PC5/6 is protective against intestinal tumorigenesis: in vivo mouse model , 2009, Molecular Cancer.

[30]  R. Day,et al.  Cutting back on pro-protein convertases: the latest approaches to pharmacological inhibition , 2005, Trends in Pharmacological Sciences.

[31]  N. Seidah,et al.  Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. , 2002, The American journal of pathology.

[32]  G. Neufeld,et al.  Semaphorin-3B is an angiogenesis inhibitor that is inactivated by furin-like pro-protein convertases. , 2008, Cancer research.

[33]  E. Ruoslahti,et al.  C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration , 2009, Proceedings of the National Academy of Sciences.

[34]  T. Clackson,et al.  Phage display : a practical approach , 2004 .

[35]  G. Thomas,et al.  Furin at the cutting edge: From protein traffic to embryogenesis and disease , 2002, Nature Reviews Molecular Cell Biology.

[36]  Erkki Ruoslahti,et al.  Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels , 2003, The Journal of cell biology.

[37]  Erkki Ruoslahti,et al.  A tumor-homing peptide with a targeting specificity related to lymphatic vessels , 2002, Nature Medicine.

[38]  N. Seidah,et al.  Comparative analysis of expression of the proprotein convertases furin, PACE4, PC1 and PC2 in human lung tumours. , 1997, British Journal of Cancer.

[39]  M. Komada,et al.  Proteolytic processing of the hepatocyte growth factor/scatter factor receptor by furin , 1993, FEBS letters.

[40]  J. Christian,et al.  Site-specific Cleavage of BMP4 by Furin, PC6, and PC7* , 2009, The Journal of Biological Chemistry.

[41]  C. Tsai,et al.  Purification and Characterization , 2006 .

[42]  A. Prat,et al.  Inhibition of Proprotein Convertases Is Associated with Loss of Growth and Tumorigenicity of HT-29 Human Colon Carcinoma Cells , 2001, The Journal of Biological Chemistry.

[43]  N. Seidah,et al.  Proprotein convertases as therapeutic targets. , 2008, Expert opinion on therapeutic targets.

[44]  W. Arap,et al.  Mapping tumor vascular diversity by screening phage display libraries. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[45]  Yan Li,et al.  Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy , 2004, Nature.

[46]  N. Seidah,et al.  Processing of alpha4 integrin by the proprotein convertases: histidine at position P6 regulates cleavage. , 2003, The Biochemical journal.

[47]  A. Klein-Szanto,et al.  Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Enbäck,et al.  Tumour-homing peptides: tools for targeting, imaging and destruction. , 2007, Biochemical Society Transactions.

[49]  D. Hanahan,et al.  Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. , 2003, Cancer cell.

[50]  Kit S Lam,et al.  Therapeutic cancer targeting peptides. , 2002, Biopolymers.

[51]  I. Fournier,et al.  TACE/ADAM‐17 maturation and activation of sheddase activity require proprotein convertase activity , 2003, FEBS letters.

[52]  P. Bühlmann,et al.  Gene Expression Signatures Identify Rhabdomyosarcoma Subtypes and Detect a Novel t(2;2)(q35;p23) Translocation Fusing PAX3 to NCOA1 , 2004, Cancer Research.

[53]  Serge Muyldermans,et al.  Efficient cancer therapy with a nanobody-based conjugate. , 2004, Cancer research.

[54]  K Nakayama,et al.  Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. , 1997, The Biochemical journal.

[55]  N. Seidah,et al.  Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides 1 Published on the World Wide Web on 17 August 1999. 1 , 1999, Brain Research.

[56]  D. Scheinberg,et al.  Monoclonal antibody therapy of cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[57]  D. Bassi,et al.  Increased furin activity enhances the malignant phenotype of human head and neck cancer cells. , 2003, The American journal of pathology.